Effect of valsartan on endothelial function, carotid intima-media thickness, left ventricular mass, arterial compliance, inflammation and coagulation abnormalities in the metabolic syndrome.
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
- 04 Jan 2012 Actual initiation date (Jan 2008) added as reported by ISRCTN: Current Controlled Trials
- 04 Jan 2012 Planned number of patients changed from 80 to 120 as reported by ISRCTN: Current Controlled Trials